First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $40.00.

A number of brokerages have weighed in on TRAX. Barclays initiated coverage on First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price target on the stock. Wedbush initiated coverage on First Tracks Biotherapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Leerink Partners initiated coverage on First Tracks Biotherapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $46.00 target price for the company. Wells Fargo & Company assumed coverage on First Tracks Biotherapeutics in a report on Monday, June 8th. They set an “overweight” rating and a $30.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They issued an “overweight” rating and a $31.00 price target on the stock.

First Tracks Biotherapeutics Stock Performance

Shares of TRAX stock opened at $36.21 on Friday. The firm has a 50-day moving average price of $19.64. The company has a market cap of $1.26 billion and a PE ratio of -19.68. First Tracks Biotherapeutics has a 52-week low of $14.72 and a 52-week high of $38.49.